The long-term results of 356 episodes of atrial defibrillation by DC shock carried out in 250 patients are reviewed.
The long-term results of 356 episodes of atrial defibrillation by DC shock carried out in 250 patients are reviewed.
In 78 per cent of the cases, atrial fibrillation recurred by the end of 12 months in spite of the administration of quinidine or procainamide or propranolol, singly or combined. However, when no antidysrhythmic drugs were used the recurrence rate was higher at all periods of observation and IOO per cent at the end of I2 months. The difference in the overall results between the untreated group and the treated groups with the exception of the propranolol group is significant (p < o.os). In addition, the propranolol group showed an obviously reduced recurrence rate at month, but afterwards the results tended to approximate those in the untreated group.
The period during which sinus rhythm could be maintained in patients who underwent valve operations was on the whole the same as in patients who did not have heart surgery. However, in a small number of patients sinus rhythm was maintained for longer periods after mitral valve replacement than before it. Sinus rhythm was maintained for significantly longer periods when atrial fibrillation lasted less than i year than when it had been present for more than i year (p < o.ooI).
It is concluded that there isjustificationfor a judicious antidysrhythmic prophylaxis after atrial defibrillation.
Since the introduction of direct current (DC) shock in the treatment of ectopic tachycardias (Lown, Amarasingham, and Neuman, I962; Oram et al., 1963) , numerous reports have appeared confirming the view that it is the most effective method of terminating atrial fibrillation and restoring sinus rhythm. However, experience has shown that the favourable immediate results (between 8o and 90%) contrast sharply with the difficulty in maintaining sinus rhythm for longer periods. In previous communications (Szekely et was restored on 389 occasions (85%). In 27 cases atrial fibrillation recurred within 24 hours. Six patients could not be traced for follow-up study. Thus, the long-term results of 356 episodes of atrial defibrillation carried out in 250 patients were available for analysis. Two hundred patients had rheumatic heart disease, 22 coronary artery disease, 4 congenital heart disease, I0 thyrotoxicosis, and I4 patients 'lone' atrial fibrillation, several of whom were suspected to have cardiomyopathy. The follow-up period ranged from i to 5 years. Antidysrhythmic agents such as quinidine sulphate, a long-acting quinidine preparation (kinidin durules), procainamide, and propranolol were used singly or in combination on 337 occasions in an attempt to prevent recurrences of atrial fibrillation, and on I9 occasions no antidysrhythmic agents were given during the follow-up period. The drugs were started as a rule 3 to 5 days before electroconversion and continued without interruption with occasional variation in the dosage until atrial fibrillation recurred. However, in August I968 we stopped giving routinely antidysrhythmic drugs before elective electroconversion and started their use within 24 hours after restoration of sinus rhythm. The last I2 patients included in this series were treated this way. Except in the very early cases, digitalis was discontinued 3 to 5 days before electroconversion, was maintained for an average of 4.5 months. All 7 patients were on antidysrhythmic drugs.
Of the 7 patients who had mitral valve replacement, in i sinus rhythm could not be restored before or after cardiac surgery. In the other 6 patients sinus rhythm was restored before cardiac surgery and it was maintained for an average period of 6 months. After cardiac surgery, sinus rhythm was again restored in these 6 patients and normal rhythm was maintained for an average period of I0 months, with only I of these 6 patients still maintaining sinus rhythm at the time of writing. All 6 patients were on antidysrhythmic drugs.
In the patient who had aortic valve replacement, sinus rhythm was maintained for i month before cardiac surgery and 4 months after it.
Coronary disease This group contains 25 episodes of atrial defibrillation carried out in 22 patients. Atrial fibrillation recurred at i month in 6 instances (24%), at 3 months in I4 instances (57%), and at the end of I2 months in I7 instances (68%).
Congenital heart disease There were 6 episodes of atrial defibrillation in 4 patients. Atrial fibrillation recurred at i month in 2 instances (33%), at 3 months in 5 instances (83%), and at the end of i2 months in 6 instances (100%).
Thyrotoxicosis Ten episodes of atrial defibrillation in io patients were studied in this group. Atrial fibrillation recurred at i month in 3 patients (30%), remaining unchanged at 3 months (30%), and at the end of i2 months in 5 patients (50%).
Lone atrial fibrillation Fourteen episodes group.bmj.com on June 22, 2017 -Published by http://heart.bmj.com/ Downloaded from of atrial defibrillation in I4 patients were included. Atrial fibrillation recurred at I month in 6 instances (43%), at 3 months in IO instances (72%), and at the end of I2 months in ii instances (78%).
Recurrence of atrial fibrillation in relation to its duration before DC shock
The data are summarized in Table 5 .
The recurrence rate of atrial fibrillation was significantly higher at all periods of observation when atrial fibrillation lasted more than one year before restoration of sinus rhythm than when it lasted less than one year. Thus, atrial fibrillation recurred in the former group of I94 cases at i month in 86 instances (48%), at 3 months in I37 instances (7I%), and at the end of I2 months in 175 instances (90% in the overall results between the untreated group and the treated groups with the exception of the propranolol group was significant (p <o0os). In addition, the propranolol group showed an obviously reduced recurrence rate at i month, but afterwards the results tended to approximate those in the untreated group. The long-term results with quinidine and procainamide were similar. The treated and untreated groups were comparable regarding underlying pathology and duration of atrial fibrillation before conversion. In patients receiving quinidine the mean serum quinidine level was found to be significantly higher when sinus rhythm was maintained than when atrial fibrillation recurred, 5 6 mg./l. and 2-9 mg./l., respectively (p <o.oi). However, the clinical significance of this finding may be limited to some extent by the fact that there were important variations in the serum quinidine levels in the individual patient, and that atrial fibrillation recurred occasionally at comparatively high serum quinidine levels. The serum quinidine level not uncommonly dropped suddenly without changing the prescribed dosage, which must have been due either to interference with absorption or to failure of taking quinidine regularly. Nevertheless, the findings suggest that a serum quinidine level less than 4 mg./l. has no protective effect. This probably applies to procainamide medication as well. We have not estimated the serum procainamide concentrations, but a recent report suggests that the effective plasma procainanilde concentration for suppressing dysrhythmias is 4 to 6 mg./l. I969) . It is possible that more regular estimations of serum concentrations of an antidysrhythmic drug and at shorter intervals with appropriate adjustments of dosage could lead to better results.
In the series of Killip and Yormak (I965), 6o per cent of the patients in whom sinus rhythm was restored maintained normal rhythm at I month, and 27 per cent at I year. Their patients were receiving quinidine or procainamide. Hills and Humphries (I967) observed a relapse rate of atrial fibrillation at I, 2, and 3 years of the order of 72, 88, and 93 per cent, respectively, but they do not mention whether the patients were receiving antidysrhythmic drugs. Bjerkelund and Orning (I968) found a 7I per cent recurrence rate of atrial fibrillation at I2 months in patients on quinidine treatment. Radford and Evans (I968) reported an overall relapse rate of 82 per cent at I2 months. Their patients on quinidine showed a lower relapse rate at i and 3 months than those without antidysrhythmic prophylaxis, but the authors discontinued quinidine after 5 months or even earlier because of unfavourable reactions. Aberg and Cullhed (I968) fibrillation. However, they also stated that discontinuation of quinidine treatment was an important factor responsible for recurrences. The duration of atrial fibrillation before conversion to sinus rhythm did influence the recurrence rate of atrial fibrillation; it was significantly higher when atrial fibrillation lasted more than i year before restoration of sinus rhythm than when it lasted less than i year (p <o0ooi). These findings are in agreement with previously reported observations (Hills and Humphries, I967; Resnekov and McDonald, I968; Bjerkelund and Orning, I968). Hills and Humphries (I967) also stated that an important factor which favoured maintenance of sinus rhythm was conversion accomplished with 200 joules or less. We found no direct correlation between the energy value used and the maintenance of sinus rhythm. It is interesting that of the 32 patients in the series of Aberg and Cullhed (I968) who maintained sinus rhythm for more than I year, 9 required 400 joules for conversion.
In a previous paper we referred to the potentiation by DC shock of the cardiotoxicity of antidysrhythmic drugs, and indeed we observed 2 episodes of ventricular fibrillation following combined quinidine and DC shock treatment (Szekely et al., I970) . On the other hand, the continuous administration of quinidine or other antidysrhythmic agents after uncomplicated DC shock therapy has not been responsible in this series for cardiotoxic effects or any serious extracardiac complications. Nevertheless, the potential cardiotoxicity of quinidine alone has been well documented (Selzer and Wray, I964; Davies, Leak, and Oram, I965) . It is possible, though conjectural, that the cardiotoxicity of procainamide is less severe. An important extracardiac complication of procainamide is now known to be lupus erythematosus (Fakhro, Ritchie, and Lown, I967). We have not observed an overt procainamide-induced lupus syndrome in any of our patients, but since the introduction of routine laboratory checks we have encountered a positive fluorescence antibody test for antinuclear factor in 5 patients, and in one of these lupus cells were found.
We believe that there is a place for the judicious use of antidysrhythmic drugs after atrial defibrillation, though admittedly the overall advantage of such a prophylactic regimen is limited. More careful adjustment of dosage schedules may perhaps result in maintenance of sinus rhythm for longer periods than hitherto achieved. The potential risks of the long-term use of antidysrhythmic drugs have to be balanced against their likely therapeutic advantages. In accordance with our previous observations (Szekely et al., I970) , and those reported by others (Aberg, I969) , our present policy is not to give antidysrhythmic drugs as pretreatment for elective electroconversion, and if conversion takes place without unwanted effects, to start antidysrhythmic prophylaxis within 24 hours after DC shock therapy.
